0
Clinical Investigations: ASTHMA |

Efficacy and Safety of Beclomethasone Dipropionate Extrafine Aerosol in Childhood Asthma*: A 12-Week, Randomized, Double-Blind, Placebo-Controlled Study

Anjuli Nayak, MD; Robert Lanier, MD; Steven Weinstein, MD; Patti Stampone; Michael Welch, MD
Author and Funding Information

*From Peoria School of Medicine (Dr. Nayak), University of Illinois, Peoria, IL; Lanier Education and Research Network (Dr. Lanier), Fort Worth, TX; Allergy and Asthma Specialists Medical Group (Dr. Weinstein), Huntington Beach, CA; 3M Pharmaceuticals (Ms. Stampone), St Paul, MN; and Allergy and Asthma Medical Group and Research Center (Dr. Welch), San Diego, CA.

Correspondence to: Anjuli Nayak, MD, Pediatrics Department, Peoria School of Medicine, University of Illinois, 1300 Franklin Ave, #180, Normal, IL 61761; e-mail: asthma2@aol.com



Chest. 2002;122(6):1956-1965. doi:10.1378/chest.122.6.1956
Text Size: A A A
Published online

Background: Beclomethasone dipropionate (BDP) has been formulated as an extrafine aerosol (hydrofluoroalkane-134a [HFA]-BDP) [QVAR; 3M Pharmaceuticals; St Paul, MN], which gives improved lung deposition compared with chlorofluorocarbon (CFC)-BDP. The clinical efficacy of HFA-BDP has been established in adult asthma at a required dose below that of CFC-BDP, but has not been evaluated in children.

Objective: To examine the efficacy and safety of HFA-BDP in childhood asthma.

Design: A 12-week, multicenter, randomized, double-blind, placebo-controlled, parallel-group study involving 353 children aged 5 to 12 years with moderate, symptomatic asthma. After a 2-week run-in period, patients were randomized to HFA-BDP, 80 μg/d (n = 120); HFA-BDP, 160 μg/d (n = 117); or HFA-placebo (n = 116) administered twice daily.

Setting: Hospital outpatient.

Results: HFA-BDP, 80 μg/d and 160 μg/d, produced a significant, dose-related increase from baseline in FEV1 percent predicted compared with placebo. At week 12, mean changes from baseline in FEV1 percent predicted were 9.2% (p ≤ 0.01 vs placebo), 10% (p ≤ 0.01 vs placebo), and 3.9% for the HFA-BDP 80 μg/d, HFA-BDP 160 μg/d, and placebo groups, respectively. There was also a significant decrease in daily β-agonist use, improvement in peak expiratory flow, and reduction in the percentage of days free from asthma symptoms (p ≤ 0.05 for HFA-BDP, 160 μg/d, vs placebo at weeks 11 to 12). HFA-BDP was well tolerated, with no significant differences in the incidence or nature of adverse events between HFA-BDP and placebo groups. Neither were there significant differences between groups in mean percentage change from baseline in the morning plasma cortisol level at week 12 or in the percentage of patients with morning plasma cortisol levels below the reference range at baseline and week 12. In a subgroup tested, the percentage of patients with an abnormal response to low-dose adrenocorticotropic hormone stimulation at week 12 was low and similar among all groups.

Conclusions: HFA-BDP, 80 to 160 μg/d, is effective and safe in childhood asthma.

Figures in this Article

Sign In to Access Full Content

MEMBER & INDIVIDUAL SUBSCRIBER

Want Access?

NEW TO CHEST?

Become a CHEST member and receive a FREE subscription as a benefit of membership.

Individuals can purchase this article on ScienceDirect.

Individuals can purchase a subscription to the journal.

Individuals can purchase a subscription to the journal or buy individual articles.

Learn more about membership or Purchase a Full Subscription.

INSTITUTIONAL ACCESS

Institutional access is now available through ScienceDirect and can be purchased at myelsevier.com.

Sign In to Access Full Content

MEMBER & INDIVIDUAL SUBSCRIBER

Want Access?

NEW TO CHEST?

Become a CHEST member and receive a FREE subscription as a benefit of membership.

Individuals can purchase this article on ScienceDirect.

Individuals can purchase a subscription to the journal.

Individuals can purchase a subscription to the journal or buy individual articles.

Learn more about membership or Purchase a Full Subscription.

INSTITUTIONAL ACCESS

Institutional access is now available through ScienceDirect and can be purchased at myelsevier.com.

Figures

Tables

References

NOTE:
Citing articles are presented as examples only. In non-demo SCM6 implementation, integration with CrossRef’s "Cited By" API will populate this tab (http://www.crossref.org/citedby.html).

Some tools below are only available to our subscribers or users with an online account.

Sign In to Access Full Content

MEMBER & INDIVIDUAL SUBSCRIBER

Want Access?

NEW TO CHEST?

Become a CHEST member and receive a FREE subscription as a benefit of membership.

Individuals can purchase this article on ScienceDirect.

Individuals can purchase a subscription to the journal.

Individuals can purchase a subscription to the journal or buy individual articles.

Learn more about membership or Purchase a Full Subscription.

INSTITUTIONAL ACCESS

Institutional access is now available through ScienceDirect and can be purchased at myelsevier.com.

Related Content

Customize your page view by dragging & repositioning the boxes below.

Find Similar Articles
CHEST Journal Articles
PubMed Articles
Guidelines
Inhaled corticosteroids for the treatment of chronic asthma in children under the age of 12 years.
National Institute for Health and Clinical Excellence (NICE) | 1/31/2008
Long-term management of asthma.
Finnish Medical Society Duodecim | 1/11/2008
  • CHEST Journal
    Print ISSN: 0012-3692
    Online ISSN: 1931-3543